| Seelos Therapeutics is a clinical-stage biopharmaceutical company focused on the development of products that address unmet needs in Central Nervous System disorders and other disorders. Co.'s primary programs are SLS-002 for the potential treatment of Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder and SLS-005 for the potential treatment of Amyotrophic Lateral Sclerosis and Spinocerebellar Ataxia. SLS-005 for the potential treatment of Sanfilippo Syndrome requires additional natural history data, which is being considered. Co. is also developing several preclinical programs, including SLS-004 and SLS-007, for the potential treatment of Parkinson's Disease. We show 20 historical shares outstanding datapoints in our coverage of SEEL's shares outstanding history.
Understanding the changing numbers of SEEL shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SEEL versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SEEL by allowing them to research SEEL shares outstanding history
as well as any other stock in our coverage universe.